Oncology Pipeline

Complix is developing a diverse pipeline of anti-cancer therapeutics based on its CPAB technology.

Pre-clinical programs

The Company is progressing several pre-clinical programs in parallel, addressing exciting and previously undruggable target classes, like transcription factors, phosphatases, regulatory proteins and nucleic acid sequences. Current targets are localized in the cytosolic space or in the nucleus of cancer cells.

Collaboration with Merck & Co

Complix is also running two programs targeting important oncogenic targets in partnership with Merck & Co.